Stelo Becomes the First Over-the-Counter Glucose Biosensor in the U.S.


On March 5, 2024, Dexcom, Inc. announced that the FDA has cleared Stelo to become the first over-the-counter glucose biosensor in the United States.

Stelo, which is indicated for persons 18 and older, allows people with non-insulin-dependent diabetes to benefit from continuous glucose monitoring (CGM) technology.

What is Stelo?

Stelo will be the first glucose biosensor in the U.S. cleared for use without a prescription.

Stelo is a compact, wearable sensor that is placed on the back of the upper arm and sends glucose data directly to the user’s smartphone.

“Based on our experience serving people with Type 2 diabetes not using insulin, we have developed Stelo with their unique needs in mind,” said Jake Leach, executive vice president and chief operating officer at Dexcom.

CGM technology enables individuals with diabetes to better understand how different diets and activities affect their blood-sugar levels.

“For people newly diagnosed with Type 2 diabetes or not taking insulin, these devices are often not covered by insurance and Stelo presents an opportunity to provide valuable information that can impact their diabetes management.” said Dr. Tamara Oser, MD, family physician.

When Will Stelo Be Available?

Stelo will be available for purchase online without a prescription beginning in summer 2024.

To learn more about Stelo and verify eligibility for Dexcom G7, visit

WRITTEN BY Dan Trecroci, POSTED 03/06/24, UPDATED 03/06/24

Dan has written about diabetes for more than 20 years. He was one of Diabetes Health's first recruits, and throughout his 10 + years as Managing Editor he wrote/published thousands of articles and helped establish Diabetes Health as the premiere resource for people with diabetes. He later became the Content Manager for OneTouchGold—Johnson & Johnson/LifeScan’s official digital publication for its metering-technology customers. Under his leadership, OneTouchGold received the Web Marketing Association’s award for “Best Health & Wellness" web site. Dan has an also written for the Diabetes Research Institute, dLife, diaTribe, Healthline, CareDx, Pendulum Therapeutics, and Hero Bread.